Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10172738 | 1.00 | ALDH1A1 (0.40) | ALDH1A1MAPTCASP6KMT2ASMN1; SMN2 | |
| SCHEMBL306818 | 0.98 | ALDH1A1 (0.39) | ALDH1A1MAPTCASP6KMT2ASMN1; SMN2 | |
| SCHEMBL307756 | 0.84 | PTGS2 (0.40) | ALDH1A1MAPTKMT2ASMN1; SMN2PTGS2 | |
| SCHEMBL306819 | 0.83 | LMNA (0.43) | ALDH1A1MAPTKMT2APTGS2 | |
| SCHEMBL18700930 | 0.82 | ALDH1A1 (0.54) | ALDH1A1MAPTKMT2ASMN1; SMN2PTGS2 | |
| SCHEMBL9751922 | 0.82 | SMN1; SMN2 (0.47) | MAPTKMT2ASMN1; SMN2MRGPRX4PTGDR2 | |
| SCHEMBL10498837 | 0.81 | ALDH1A1 (0.52) | ALDH1A1MAPTKMT2ASMN1; SMN2PTGS2 | |
| Hydrochloric Acid SCHEMBL28105953 | 0.81 | ALDH1A1 (0.52) | ALDH1A1MAPTKMT2ASMN1; SMN2PTGS2 | |
| Nitrogen SCHEMBL28639385 | 0.79 | ALDH1A1 (0.51) | ALDH1A1MAPTKMT2ASMN1; SMN2PTGS2 | |
| SCHEMBL12909005 | 0.79 | MCOLN3 (0.43) | ALDH1A1KMT2APTGS2S1PR3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470860-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2013-06-25 | — | — | US | disclosed |
| EP-1966166-B1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | STERIX LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8022224-B2 | 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors | STERIX LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX, LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-7763642-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LTD. (GB) | 2010-07-27 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| EP-1753732-B1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | STERIX LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| EP-1966166-A1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | Sterix Limited (GB) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068905-A1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | STERIX LIMITED (GB) | 2007-06-21 | — | — | WO | disclosed |
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2007-05-24 | — | — | US | disclosed |
| EP-1753732-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | Sterix Limited (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118560-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX LIMITED (GB) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | CYP19A1, CYP17A1, CYP21A2 | ALDH1A1 1209/4885MAPT 4467/4885CASP6 4063/4885 |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | CYP19A1, CYP21A2, CBR1 | ALDH1A1 625/4885MAPT 4869/4885CASP6 3395/4885 |
| US-20100173963-A1 | COMPOUND | CBR3, CBR1, OXSR1 | ALDH1A1 1841/4885MAPT 4768/4885CASP6 3167/4885 |
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | CYP19A1, CYP17A1, CYP21A2 | ALDH1A1 1209/4885MAPT 4467/4885CASP6 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.